CGCF @ GW-ICC Joint Forum – Great Wall International Congress of Cardiology (GW-ICC) 2017 – Safety and Efficacy Results in the EWOLUTION Trial – Special Focus on the DAPT Subgroup

It has become a tradition for world renowned cardiology associations to send delegations to GW-ICC congresses.

Cooperation with these international societies is not limited to their attendance at GW-ICC; GW-ICC also holds reciprocal academic sessions at the annual meetings of these eminent societies, for example GW-ICC @ ACC, GW-ICC @ AHA, and GW @ ESC, to introduce important Chinese academic research.

At the 28th GW-ICC in 2017, the China-German Cardiovascular Forum (CGCF) held a Joint session – New Trends on Valvular Heart Disease and Coronary Heart Disease. A video of one of these 2017 sessions is now available to view on the GW-ICC YouTube channel:

Safety and Efficacy Results in the EWOLUTION Trial – Special Focus on the DAPT Subgroup

Presenter: Sven Möbius-Winkler, Friedrich Schiller University Jena, Jena, Germany.

Professor Möbius-Winkler discusses how:

  • One-year outcome data following LAA closure with the WATCHMAN device find a safety profile as low as other left atrial procedures.
  • Bleeding with DAPT is the most relevant SAE.
  • Efficacy regarding stroke prevention in this high risk, mostly OAC ineligible patient cohort is similar to randomized trials with OAC eligible patients.
  • Stroke rate in EWOLUTION DAPT subgroup is similar to ARISTOTLE subgroup CHA2DS2-VASc>
  • The 2016 ESC guidelines on atrial fibrillation recommending LAA closure for patient contraindicated for adequate N(OAC) therapy where supported by EWOLUTION one-year results.

Further information on the 29th GW-ICC, to be held October 11th -14th, 2018, in Beijing, China, is available on the congress website:

 Cardiovascular Innovations and Applications (CVIA) is the official journal of the Great Wall International Cardiology Conference (GW-ICC). CVIA supports GW-ICC in its aims of leading the development of cardiovascular medicine in China, by introducing and promoting new concepts and technologies and strengthening and promoting cooperation amongst Chinese and international cardiology experts. CVIA is available on the IngentaConnect platform and at Submissions may be made using Scholar One manuscripts at https:/ There are no author submission or article processing fees.

Twitter: @CVIA_Journal


Conference website:

Updated: November 26, 2020 — 12:35 pm